The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

vigencell.com

Founded Year

2013

Stage

IPO | IPO

Total Raised

$26.34M

Date of IPO

8/1/2021

Market Cap

180.16B

About ViGenCell

ViGenCell (KOSDAQ: 308080) is a biotechnology company that develops immune cell therapy technologies to treat tumors by improving patient's immunity in parallel with conventional cancer treatments such as surgery, drug therapy, and radiation therapy. It was founded in 2013 and is based in Seoul, South Korea.

ViGenCell Headquarters Location

Sungeui Hall 1321 222 Banpo-daero, Seocho-gu

Seoul, 06591,

South Korea

+82-70-4348-7457

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ViGenCell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ViGenCell is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest ViGenCell News

Korean bio companies expand production capacity to win more CMO works

Oct 27, 2021

Korean bio companies expand production capacity to win more CMO works 바로가기 기자명 Shim Hyun-tai 닫기 Korean biotech companies are jumping into the drug contract manufacturing (CMO) business and increasing their production capacity to secure a stable source of income. Many bio ventures in the nation, such as Bioneer, Humedix, ViGenCell, and Genome & Company, have already begun expanding or preparing to secure more production facilities, following the road other large domestic biopharmaceutical companies had taken. Domestic biotech companies rush to increase their production capacity and dive into the drug contract manufacturing (CMO) business. Biotech companies tend to look for a chance to enter the CMO business to generate stable profits compared to the new drug candidates under development, which is difficult to expect visible income. Bioneer is near the end of its construction of the global center in Daejeon that started in Nov. 2020. The company expects to have an eight-time larger production capacity once it begins operating the facilities. "When we complete building up the global center plant, we would be able to make eight-times more of the current supply of nucleic acid extractors, polymerase chain reaction (PCR) devices, and diagnostic reagents," Bioneer official said. "Our newly built center will allow us to take large-scale orders from overseas for manufacturing products worth up to 1 trillion won ($855 million) per year." Humedix also rushed to expand its lines for making vials at the second plant located in Jecheon, North Chungcheong Province. The company's decision to expand the capacity was to produce more than 100 million doses per month. The company joined the Huons Global Consortium and is now in charge of filling vials and packaging Russia's Sputnik V Covid-19 vaccine. Once the expansion is completed, the company will secure the capacity to accept more CMO deals and increase manufacturing existing products, including Revitalrex and Hudaxin, along with Sputnik V production. Boryung Pharmaceutical's affiliate ViGenCell started constructing a facility for accelerating clinical trials and mass production of its immune cell therapy this month. The facility, which is scheduled to be completed in the first half of 2022, would have the capacity for mass production with seven cleanrooms and an automated process system. ViGenCell designed the plant to include a facility for living modified organisms, making the company one of the few in Korea that can produce cell therapy and cell gene therapy together. Another domestic biotech company, Genome & Company, acquired the management rights of List Labs, a U.S.-based company providing CDMO service in the microbiome, saying it would leap an integrated pharmaceutical company by increasing its mid-to-long-term production capacity. Based on stable profits from the partnership with List Labs, Genome & Company plan to develop its flagship microbiome treatment and reach annual sales of 100 billion won by 2025 through additional production capacity expansion. Other large domestic drug makers like Samsung Biologics and SK Bioscience have one the largest production facilities globally and highlighted by consignment production of multinational pharmaceutical companies' Covid-19 vaccines are also pushing their plans for expanding capacity.

ViGenCell Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ViGenCell Rank

  • When was ViGenCell founded?

    ViGenCell was founded in 2013.

  • Where is ViGenCell's headquarters?

    ViGenCell's headquarters is located at Sungeui Hall 1321, Seoul.

  • What is ViGenCell's latest funding round?

    ViGenCell's latest funding round is IPO.

  • How much did ViGenCell raise?

    ViGenCell raised a total of $26.34M.

  • Who are the investors of ViGenCell?

    Investors of ViGenCell include Shinhan Venture Investment, DAYLI Partners, TIGRIS investment, Premier Partners, Boryung Pharmaceutical and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.